The WHO 2022 is more conservative and still maintains the entity MDS with low blasts and ring sideroblasts in cases with wild-type SF3B1 and ≥15% ring sideroblasts [2]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.